{
    "other_tests": [
        {
            "procedure_name": "Buprenorphine Treatment",
            "date": "Not specified",
            "findings": "Ms. B was started on a daily dose of 8 mg/2 mg of buprenorphine-naloxone, which was increased to 12 mg/3 mg on day 2 and then to 24 mg/6 mg by the third week; at this point, she reported that opioid cravings and withdrawal were suppressed for the entire day.",
            "changes_over_time": "Initially, she experienced mild residual withdrawal symptoms, but as treatment progressed, she became more comfortable with continuing buprenorphine-naloxone for an indefinite period. Later, after relapsing, she was restarted on buprenorphine-naloxone and sertraline, which was titrated to 300 mg/day."
        },
        {
            "procedure_name": "Sertraline Trial",
            "date": "2nd week after initiation of treatment",
            "findings": "Ms. B began a trial of sertraline for her depressive symptoms.",
            "changes_over_time": "After a reduction in sertraline dosage from 200 to 150 mg/day due to anorgasmia, her depressive symptoms returned, leading to restoration of the dosage to 200 mg, but the depression did not improve. She was then switched to escitalopram, producing only modest improvement."
        }
    ]
}